Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?

被引:60
|
作者
Nagy, Gyoergy [1 ,2 ]
van Vollenhoven, Ronald F. [3 ]
机构
[1] Semmelweis Univ, Fac Med, Dept Rheumatol, H-1023 Budapest, Hungary
[2] Semmelweis Univ, Fac Med, Dept Genet Cell & Immunobiol, H-1089 Budapest, Hungary
[3] Karolinska Inst, Unit Clin Therapy Res Inflammatory Dis ClinTRID, S-17176 Stockholm, Sweden
关键词
LOW DISEASE-ACTIVITY; ADALIMUMAB PLUS METHOTREXATE; DOUBLE-BLIND; INDUCTION THERAPY; CONTROLLED-TRIAL; PHASE-II; INFLIXIMAB; MONOTHERAPY; OPPORTUNITY; WINDOW;
D O I
10.1186/s13075-015-0707-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The advent of new medications and new treatment strategies for rheumatoid arthritis has made it possible to achieve remission in more patients than before. Furthermore, recent clinical trials and register studies suggest that some patients who initially required aggressive therapy may achieve biologic-free remission or even the ultimate goal of therapy, drug-free remission, resembling recovery. Here, we present a discursive review of the most important studies addressing these issues. Based on the overall results, it remains unclear if achieving biologic-free and drug-free remissions are primarily due to the natural course of the disease or to the early therapeutic intervention according to the 'window of opportunity' hypothesis. Although medication-free remission is only achievable in a small subset of patients, characterizing this patient cohort may provide important information about beneficial prognostic factors and the underlying mechanisms. In summary, in a subset of patients biologic-free and even drug-free remission can be achieved; pursuing these possibilities in practice may decrease the risk for long-term side effects and attenuate the economic burden of the disease.
引用
下载
收藏
页数:7
相关论文
共 50 条
  • [31] Prevalence of and Predictive Factors for Sustained Disease-Modifying Antirheumatic Drug-Free Remission in Rheumatoid Arthritis Results From Two Large Early Arthritis Cohorts
    van der Woude, Diane
    Young, Adam
    Jayakumar, Keeranur
    Mertens, Bart J.
    Toes, Rene E. M.
    van der Heijde, Desiree
    Huizinga, Tom W. J.
    van der Helm-van Mil, Annette H. M.
    ARTHRITIS AND RHEUMATISM, 2009, 60 (08): : 2262 - 2271
  • [32] ON DRUG AND DRUG-FREE REMISSION BY BASELINE DISEASE DURATION: ABATACEPT VERSUS METHOTREXATE COMPARISON IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
    Bykerk, V. P.
    Burmester, G. R.
    Combe, B. G.
    Furst, D. E.
    Huizinga, T. W. J.
    Wong, D. A.
    Emery, P.
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 42 - 42
  • [33] Correction to: On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis
    Vivian P. Bykerk
    Gerd R. Burmester
    Bernard G. Combe
    Daniel E. Furst
    Tom W. J. Huizinga
    Harris A. Ahmad
    Paul Emery
    Rheumatology International, 2019, 39 : 945 - 945
  • [34] On Drug and Drug-Free Remission By Baseline Disease Duration: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis
    Bykerk, V. P.
    Burmester, Gerd
    Combe, B. G.
    Furst, Daniel E.
    Huizinga, T. W. J.
    Wong, D. A.
    Emery, Paul
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [35] Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry
    Yoshida, Kazuki
    Kishimoto, Mitsumasa
    Radner, Helga
    Matsui, Kazuo
    Okada, Masato
    Saeki, Yukihiko
    Solomon, Daniel H.
    Tohma, Shigeto
    RHEUMATOLOGY, 2016, 55 (02) : 286 - 290
  • [36] Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?
    Liu, Di
    Yuan, Na
    Yu, Guimei
    Song, Ge
    Chen, Yan
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (08): : 3758 - 3775
  • [37] Improved outcomes of drug-free remission with DAS-steered therapy compared to conventional therapy for rheumatoid arthritis
    van der Woude, D.
    Visser, K.
    Brand, R.
    Klarenbeek, N. B.
    van der Linden, M. P. M.
    Mailee, C.
    de Beus, W. M.
    Kerstens, P. J. S. M.
    Dijkmans, B. A. C.
    Huizinga, T. W. J.
    Mil, A. H. M. van der Helm-van
    Allaart, C. F.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S919 - S920
  • [38] Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study (vol 105, 102298, 2019)
    Baker, Kenneth F.
    Skelton, Andrew J.
    Lendrem, Dennis W.
    Scadeng, Adam
    Thompson, Ben
    Pratt, Arthur G.
    Isaacs, John D.
    JOURNAL OF AUTOIMMUNITY, 2022, 132
  • [39] Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies
    van der Woude, Diane
    Visser, Karen
    Klarenbeek, Naomi B.
    Ronday, H. Karel
    Peeters, Andre J.
    Kerstens, Pit J. S. M.
    Dijkmans, Ben A. C.
    Huizinga, Tom W. J.
    van der Helm-van Mil, Annette H. M.
    Allaart, Cornelia F.
    RHEUMATOLOGY, 2012, 51 (06) : 1120 - 1128
  • [40] Role of neuroimmunomodulation by vagus nerve stimulation in rheumatoid arthritis: Are we heading towards a drug-free era?
    Rath, Prasan Deep
    Pandey, Swetal
    Bisaralli, Rahul
    INDIAN JOURNAL OF RHEUMATOLOGY, 2020, 15 (04) : 323 - 332